Atul Deshpande, Harbour BioMed chief strategy officer & head, US operations (Harbour BioMed)

July 9, 2020 07:00 AM EDTUpdated 10:14 AM

Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace

Max Gelman

Senior Editor

A short four months after announcing a $75 million haul in Series B+ fundraising, the multinational biotech Harbour BioMed pulled in another round of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace

Max Gelman

Senior Editor

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

FDA approves first drug to treat ultra-rare lipid storage disease

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Trump blog: Judge extends nationwide block on NIH payment cuts

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

An­oth­er biotech IPO set-up? Multi­na­tion­al biotech leaps from round to round, scoop­ing up cash at a blis­ter­ing pace

Max Gelman

Senior Editor

Sign up to read this article for free.

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA says Ozem­pic, We­govy short­age is over

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace

CBER's deputy director departs as staff shakeup continues

FDA approves first drug to treat ultra-rare lipid storage disease

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Trump blog: Judge extends nationwide block on NIH payment cuts

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence